Dechra Pharmaceuticals PLC (GB:DPH)

Dechra Pharmaceuticals (DPH) Financial Statements


Dechra Pharmaceuticals Financial Overview

Dechra Pharmaceuticals's market cap is currently ―. The company's EPS TTM is p-0.245; its P/E ratio is -167.24; and it has a dividend yield of 1.18%. Dechra Pharmaceuticals is scheduled to report earnings on February 26, 2024, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Jun 22Dec 21Jun 21Dec 20
Income Statement-
Total Revenue-----
Gross Profit-----
Net Income Common Stockholders-----
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments£ 87.90M£ 120.90M£ 123.70M£ 118.40M£ 139.00M
Total Assets£ 1.74B£ 1.29B£ 1.18B£ 1.21B£ 1.21B
Total Debt£ 511.20M£ 329.10M£ 316.80M£ 318.60M£ 343.00M
Net Debt£ 423.30M£ 208.20M£ 193.10M£ 200.20M£ 204.00M
Total Liabilities£ 902.60M£ 626.50M£ 538.60M£ 581.20M£ 580.50M
Stockholders Equity£ 841.70M£ 666.80M£ 639.10M£ 632.90M£ 625.40M
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in GBP

Dechra Pharmaceuticals Earnings and Revenue History

Dechra Pharmaceuticals Debt to Assets

Dechra Pharmaceuticals Cash Flow

Dechra Pharmaceuticals Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis